ArticleBiochemistry and biophysics reports2026
Exploring the protease inhibitory potential of 2-bromo-2-nitro-1,3- propanediol (Bronopol): Initial findings.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The compound 2-bromo-2-nitropropane-1,3-diol also known as Bronopol (BP) is a widely used antimicrobial preservative which highly soluble in water. Although its antimicrobial mechanism has been well described, its potential to modulate protease activity has not been previously examined. Proteases represent one of the largest and most industrially important classes of enzymes, and protease inhibitors are essential tools in research, biotechnology, and therapeutic development. In this study, we investigated the ability of BP to inhibit serine, cysteine, and aspartic proteases using both synthetic and natural proteins. Protease inhibition was quantified using trypsin, proteinase K, papain, and pepsin. BP produced a clear dose-dependent inhibition of all proteases tested, with distinct sensitivity profiles. Proteinase K and trypsin activities declined progressively across 50-1000 μM BP, reaching approximately 20% residual activity at the highest concentration. Papain showed the greatest susceptibility, exhibiting near-complete inhibition (>95%) at 500-1000 μM. Pepsin displayed modest inhibition at low BP concentrations but substantial loss of activity above 250 μM. Proteolytic cleavage of bovine serum albumin (BSA) and ovalbumin were assessed by SDS-PAGE. Proteinase K alone caused extensive degradation of both substrates; however, BP at 2500-10 000 μM markedly reduced proteolysis and preserved full-length proteins, confirming protective effects observed in enzymatic assays. Together, these findings identify BP as an inhibitor of serine, cysteine, and aspartic proteases, with potent effects at moderate to high concentrations. This previously unreported activity suggests additional functional roles for BP in biochemical systems and highlights its potential relevance in research and industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.